Barclays raised price target on Hims & Hers Health and announced a partnership to sell weight-loss drugs via its platform.
1 report, 1 independent
Updated Jun 18
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Barclays raised price target on Hims & Hers Health and announced a partnership to sell weight-loss drugs via its platform.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Hims & Hers Health
American telehealth company
Nothing else this week.
-
Barclays
British bank
-
Novo Nordisk
Danish pharmaceutical company
Related events
- Barclays lifted its share target for Strategy on October 1, 2026.
- Leerink Partners and Barclays raised price targets on Elevance Health, while MarketBeat reported consensus ratings.
- Eli Lilly and Novo Nordisk are competing for market share in the weight loss drug sector.
- Multiple major banks, including Citigroup, UBS, Bank of America, and Barclays, have issued updated price targets and ratings.